Several molecules have been selected as candidate targets for MM immunotherapies, including signaling lymphocytic activation molecule (SLAM) family 7 (SLAMF7) and CD38, which are targeted by elotuzumab and daratumumab/isatuximab, respectively, and other cell-surface antigens such as B-cell maturation antigen (BCMA), CD56, CD138, CD74, interleukin (IL)-6 receptor, vascular endothelial growth factor (VEGF), and activated conformation of integrin β7 [11,12,13]. Here, TNFRSF17 is linked to Miyoshi myopathy.